Investor Relations | Alnylam Pharmaceuticals, Inc.

Learn more about Alnylam’s response to COVID-19 ›

EVENTS & PRESENTATIONS

May 01, 2025 / 08:30 AM EDT

Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call

Apr 08, 2025

Needham 24th Annual Virtual Healthcare Conference

Past Events ›

Feb 25, 2025

Alnylam 2025 R&D Day

Past Events ›

View all events and presentations ›

2024 Annual Report

2023 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q4 2024 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2025 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

Apr 17, 2025

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Apr 01, 2025

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Mar 29, 2025

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

View all press releases ›